A 55-year-old Asian man was diagnosed as mantle cell lymphoma in 2004. He received conventional chemotherapy followed by autologous peripheral blood stem cell transplantation and achieved complete remission in 2004. The disease relapsed in 2007, and he underwent bone marrow transplantation from an unrelated donor after conditioning with fludarabine 30 mg/m 2 once daily i.v. for 5 days (total dose 150 mg/m 2 ) and cyclophosphamide 1 g/m 2 once daily i.v. for 2 days (total dose 2 g/m 2 ). He received tacrolimus and shortterm methotrexate for graft-vs-host disease (GVHD) prophylaxis and achieved complete remission on day 89. On day 663, at the age of 61, he was referred to the emergency department of Nagoya University Hospital because of a 2-day history of fever and appetite loss. On initial evaluation, he was febrile (temperature : 38.5°C) with a pulse rate of 113 beats/min, blood pressure of 97/69 mmHg, respiratory rate of 20 breaths/min, and saturation of 88% at room air. He required 3 L of supplemental oxygen, which was supplied using a face mask, to maintain an oxygen saturation of 99% ＞ A nasopharyngeal swab collected in the emergency department was negative for influenza A by rapid antigen testing. The patient had been immunized against seasonal influenza, but not against H1N1 influenza.
Shigeki Saito, 2) Miki Kobayashi, 1, 2) Akari Kodaira, 6 ) Shinichiro Shibata, 6) Isao Oda, 7) Tetsuya Yagi, 3) Hitoshi Kiyoi, 3) Tadashi Matsushita, 4) Tetsuhito Kojima, 5) and Tomoki Naoe 2) Keywords: virus-associated hemophagocytic syndrome, bone marrow transplantation, H1N1 influenza
To the Editor
A 55-year-old Asian man was diagnosed as mantle cell lymphoma in 2004. He received conventional chemotherapy followed by autologous peripheral blood stem cell transplantation and achieved complete remission in 2004. The disease relapsed in 2007, and he underwent bone marrow transplantation from an unrelated donor after conditioning with fludarabine 30 mg/m 2 once daily i.v. for 5 days (total dose 150 mg/m 2 ) and cyclophosphamide 1 g/m 2 once daily i.v. for 2 days (total dose 2 g/m 2 ). He received tacrolimus and shortterm methotrexate for graft-vs-host disease (GVHD) prophylaxis and achieved complete remission on day 89. On day 663, at the age of 61, he was referred to the emergency department of Nagoya University Hospital because of a 2-day history of fever and appetite loss. On initial evaluation, he was febrile (temperature : 38.5°C) with a pulse rate of 113 beats/min, blood pressure of 97/69 mmHg, respiratory rate of 20 breaths/min, and saturation of 88% at room air. He required 3 L of supplemental oxygen, which was supplied using a face mask, to maintain an oxygen saturation of 99% ＞ A nasopharyngeal swab collected in the emergency department was negative for influenza A by rapid antigen testing. The patient had been immunized against seasonal influenza, but not against H1N1 influenza.
On arrival at the hematology-oncology department, lymphadenopathy or skin rash was not observed in the patient. He did not take any immunosuppressive agents, having no sign of chronic GVHD at that time. Initial laboratory findings showed a hemoglobin level of 12.4 g/dL, hematocrit of 35. 9%, platelet count of 141,000/mm 3 , and white blood cell (WBC) count of 13,200/mm 3 with an absolute neutrophil count of 6,700/mm 3 . The chemistry profile showed that sodium, potassium, chloride, blood urea nitrogen, creatinine, glucose, asparate aminotransferase (AST), alanine aminotransferase (ALT), and lactate dehydrogenase (LDH) were all within normal limits. The C-reactive protein (CRP) level was 7.6 mg/dL. Serum endotoxin and b-D glucan were negative. Serum immunoglobulin G, A, M level was 2,242, 27 and 156 mg/dL, respectively, and maintains the comparable level throughout the course. Soluble interleukin-2 receptor level was 1,360 U/mL. A chest radiograph was normal. A computed tomography scan of the chest was also normal. The patient showed no evidence of recurrence of lymphoma. A blood culture was obtained, and he received a dosage of intravenous imipenem/cilastatin (0.5 g×2/day).
On hospital day 9, the patient's clinical condition worsened with progressive dyspnea and hypoxia. The nasopharyngeal swab tested positive for influenza A by rapid antigen testing. A definite diagnosis was based on a positive result for pandemic H1N1 influenza virus by real-time reverse transcription-PCR (RT-PCR) for a nasopharyngeal swab. Oseltamivir (75 mg×2/day) was started on hospital day 9. Repeat laboratory data showed pancytopenia with a hemoglobin level of 9.3 g/dL, hematocrit of 28.1%, platelet count of 29,000/mm 3 , and WBC count of 3,700/mm 3 with an absolute neutrophil count of 1,700/mm 3 (Fig. 1) . A high-resolution computed tomography (HRCT) scan of the chest revealed bilateral and peripheral focal ground-glass opacities in the upper, middle, and lower zones that are typical in H1N1 pneumonia (Fig.  2) .
1,2 Multiple blood, urine, and sputum cultures were negative for bacteria and fungi. The patient's cytomegalovirus (CMV) antigenemia was negative. On hospital day 11, the repeat chemistry profile revealed an AST of 542 IU/L, ALT of 388 IU/L, LDH of 883 IU/L, and ferritin level of 8,814 ng/mL. As this patient met the criteria for the diagnosis of VAHS, 3 empiric treatment was initiated with 1 mg/kg of prednisolone on day 11, with subsequent reduction in fever. AST, ALT, and LDH levels became normal on hospital days 25, 36, and 25, respectively. The serum ferritin level decreased to 862 ng/mL on hospital day 22. The patient remained in a stable physical condition with a gradual dose reduction of prednisolone.
Pandemic (H1N1) influenza virus first appeared in March 2009 in Mexico and its rapid spread throughout the world marked the beginning of the first influenza pandemic in more than 40 years. 4, 5 VAHS is an unusual disorder characterized by uncontrolled proliferation of mature histiocytes exhibiting hemophagocytosis. 3 A previous study demonstrated 6 of 68 (8.8%) cases of VAHS after allogeneic stem cell transplantation. 6 One case was infected with Epstein-Barr virus, 2 cases with CMV, and 3 cases showed no evidence of bacterial, fungal, or viral infections. Previous reports demonstrated VAHS associated with H3N2 seasonal influenza, 7, 8 however, to the best of our knowledge, this patient represents the first report of VAHS associated with H1N1 influenza pneumonia. Physicians taking care of patients with hematologic malignancies should be aware of VAHS as an unusual but potentially severe and life-threatening complication of H1N1 influenza in immunosuppressed individuals. The most common HRCT manifestations of H1N1 virus-associated pneumonia are bilateral ground-glass opacities and/or bilateral areas of consolidation, which showed a more severe clinical course. 1 Early computed tomography may help clinicians recognize incipient cases of H1N1 virus-associated pneumonia.
